Vrati se na sadržaj

Beta talasemija intermedia i minor

Potporna terapija

Vezivanje gvožđa

Iron out for nontransfused thalassemia. (otvara novi prozor)

Marks PW.

Izvor‎: Blood 2012;120(5):928-9.

Indeks‎: PubMed 22859709

DOI‎: 10.1182/blood-2012-06-433227

https://www.ncbi.nlm.nih.gov/pubmed/22859709 (otvara novi prozor)

Iron overload in β-thalassemia intermedia: an emerging concern. (otvara novi prozor)

Musallam KM, Cappellini MD, Taher AT.

Izvor‎: Curr Opin Hematol 2013;20(3):187-92.

Indeks‎: PubMed 23426199

DOI‎: 10.1097/MOH.0b013e32835f5a5c

https://www.ncbi.nlm.nih.gov/pubmed/23426199 (otvara novi prozor)

Dijetetski suplementi i druge potporne terapije

Treatment with bosentan in a patient with thalassemia intermedia and pulmonary arterial hypertension. (otvara novi prozor)

Anthi A, Tsangaris I, Hamodraka ES, Lekakis J, Armaganidis A, Orfanos SE.

Izvor‎: Blood 2012;120(7):1531-2.

Indeks‎: PubMed 22899478

DOI‎: 10.1182/blood-2012-04-422568

https://www.ncbi.nlm.nih.gov/pubmed/22899478 (otvara novi prozor)

Prevalance of iron deficiency in thalassemia minor: a study from tertiary hospital. (otvara novi prozor)

Dolai TK, Nataraj KS, Sinha N, Mishra S, Bhattacharya M, Ghosh MK.

Izvor‎: Indian J Hematol Blood Transfus 2012;28(1):7-9.

Indeks‎: PubMed 23449336

DOI‎: 10.1007/s12288-011-0088-9

https://www.ncbi.nlm.nih.gov/pubmed/23449336 (otvara novi prozor)

Therapeutic roles of curcumin: lessons learned from clinical trials. (otvara novi prozor)

Gupta SC, Patchva S, Aggarwal BB.

Izvor‎: AAPS J 2013;15(1):195-218.

Indeks‎: PubMed 23143785

DOI‎: 10.1208/s12248-012-9432-8

https://www.ncbi.nlm.nih.gov/pubmed/23143785 (otvara novi prozor)

Vitamin E supplement improves erythrocyte membrane fluidity of thalassemia: an ESR spin labeling study. (otvara novi prozor)

Sutipornpalangkul W, Morales NP, Unchern S, Sanvarinda Y, Chantharaksri U, Fucharoen S.

Izvor‎: J Med Assoc Thai 2012;95(1):29-36.

Indeks‎: PubMed 22379738

https://www.ncbi.nlm.nih.gov/pubmed/22379738 (otvara novi prozor)

Deferasirox demonstrates a dose-dependent reduction in liver iron concentration and consistent efficacy across subgroups of non-transfusion-dependent thalassemia patients. (otvara novi prozor)

Taher AT, Porter JB, Viprakasit V, Kattamis A, Chuncharunee S, Sutcharitchan P, Siritanaratkul N, Galanello R, Karakas Z, Lawniczek T, Habr D, Ros J, Zhang Y, Cappellini MD.

Izvor‎: Am J Hematol 2013;88(6):503-6.

Indeks‎: PubMed 23553596

DOI‎: 10.1002/ajh.23445

https://www.ncbi.nlm.nih.gov/pubmed/23553596 (otvara novi prozor)